Femasys’ (FEMY) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Femasys (NASDAQ:FEMY) in a report issued on Thursday morning, Benzinga reports. Chardan Capital currently has a $12.00 price target on the stock.

A number of other equities analysts have also issued reports on the stock. Jonestrading boosted their target price on shares of Femasys from $7.00 to $10.00 and gave the stock a buy rating in a research report on Wednesday. HC Wainwright reiterated a buy rating and set a $10.00 price target on shares of Femasys in a research report on Thursday.

Femasys Stock Performance

NASDAQ:FEMY opened at $1.72 on Thursday. Femasys has a 12 month low of $0.25 and a 12 month high of $4.75. The company’s 50 day moving average is $1.32 and its 200-day moving average is $1.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.68 and a quick ratio of 4.40.

Institutional Trading of Femasys

Institutional investors and hedge funds have recently modified their holdings of the stock. Clear Creek Financial Management LLC increased its stake in Femasys by 4.1% during the 3rd quarter. Clear Creek Financial Management LLC now owns 232,519 shares of the company’s stock worth $693,000 after purchasing an additional 9,230 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in Femasys in the 3rd quarter valued at $35,000. Cetera Advisor Networks LLC bought a new position in Femasys during the 1st quarter worth $27,000. Virtu Financial LLC bought a new position in Femasys during the 2nd quarter worth $39,000. Finally, Vanguard Group Inc. increased its position in Femasys by 15.1% during the 3rd quarter. Vanguard Group Inc. now owns 137,133 shares of the company’s stock worth $155,000 after buying an additional 17,948 shares during the period. 8.29% of the stock is owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.